HLA-DRA and nonpapillary renal cell carcinoma: To ensure the reliability of our conclusions, we conducted IHC testing for HLA-DRA expression on 150 ccRCC tissues using an independent in-house dataset (4 out of 150 cases were not included in the statistics due to a missing IHC testing process) (Figure 3F).